Akari Therapeutics, Plc (AKTX)

Market Cap	43.44M
Revenue (ttm)	n/a
Net Income (ttm)	-17.93M
Shares Out	32.18M
EPS (ttm)	-1.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,388
Open	1.290
Previous Close	1.300
Day's Range	1.201 - 1.350
52-Week Range	0.850 - 4.400
Beta	0.29
Analysts	n/a
Price Target	n/a
Earnings Date	May 15, 2025

About AKTX

Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) and a novel discovery engine. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. In addition, its payloads include PH5, which inhibits DNA mism...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Abizer Gaslightwala
• Employees: 9
• Stock Exchange: NASDAQ
• Ticker Symbol: AKTX
• Website: https://www.akaritx.com